Compare NSA & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSA | ADMA |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | 1458 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | N/A | 2012 |
| Metric | NSA | ADMA |
|---|---|---|
| Price | $42.00 | $10.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $34.38 | $25.67 |
| AVG Volume (30 Days) | 923.9K | ★ 4.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | N/A | $27.46 |
| Revenue Next Year | $2.39 | $22.11 |
| P/E Ratio | $56.31 | ★ $17.16 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $27.43 | $7.21 |
| 52 Week High | $44.02 | $23.98 |
| Indicator | NSA | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 39.94 |
| Support Level | $27.89 | $7.21 |
| Resistance Level | $44.02 | $11.42 |
| Average True Range (ATR) | 1.02 | 0.48 |
| MACD | -0.36 | 0.10 |
| Stochastic Oscillator | 27.39 | 15.69 |
National Storage Affiliates Trust Trust is a real estate investment trust. The company owns, operates, and acquires self-storage properties located within the metropolitan statistical areas throughout the United States. With the help of property management platform, the company manages and controls the day-to-day operations and affairs of consolidated properties and unconsolidated real estate ventures under the iStorage, SecurCare, RightSpace, Northwest and Move It brands.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.